Blockchain Registration Transaction Record

NEC Bio Therapeutics and AGC Biologics Announce Collaboration to Manufacture Personalized Cancer Vaccines

NEC Bio Therapeutics and AGC Biologics announce a significant collaboration to advance the production of NECVAX-NEO1, a personalized cancer vaccine targeting patient-specific tumor neoantigens. This collaboration represents a major advancement in personalized cancer treatments and has the potential to revolutionize the way cancer is treated, offering new hope to countless individuals battling the disease.

This news matters because the collaboration between NEC Bio Therapeutics and AGC Biologics represents a significant advancement in the production of personalized cancer treatments, particularly NECVAX-NEO1, a novel orally delivered, bacteria-based DNA vaccine designed to target patient-specific tumor neoantigens. This partnership has the potential to revolutionize the way cancer is treated, offering new hope to countless individuals battling the disease. The collaboration also underscores the dedication of both companies to improving global health outcomes in the oncology field.